TW200507839A - Therapeutic agents - Google Patents
Therapeutic agentsInfo
- Publication number
- TW200507839A TW200507839A TW092136000A TW92136000A TW200507839A TW 200507839 A TW200507839 A TW 200507839A TW 092136000 A TW092136000 A TW 092136000A TW 92136000 A TW92136000 A TW 92136000A TW 200507839 A TW200507839 A TW 200507839A
- Authority
- TW
- Taiwan
- Prior art keywords
- optionally substituted
- group
- 3alkyl
- groups
- nitrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0230087.9A GB0230087D0 (en) | 2002-12-24 | 2002-12-24 | Therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200507839A true TW200507839A (en) | 2005-03-01 |
Family
ID=9950372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW092136000A TW200507839A (en) | 2002-12-24 | 2003-12-18 | Therapeutic agents |
Country Status (20)
Country | Link |
---|---|
US (1) | US20060122229A1 (zh) |
EP (1) | EP1581214A1 (zh) |
JP (1) | JP2006516137A (zh) |
KR (1) | KR20050085691A (zh) |
CN (1) | CN1753672A (zh) |
AR (1) | AR042659A1 (zh) |
AU (1) | AU2003290280A1 (zh) |
BR (1) | BR0317703A (zh) |
CA (1) | CA2511603A1 (zh) |
CO (1) | CO5580768A2 (zh) |
GB (1) | GB0230087D0 (zh) |
IS (1) | IS7945A (zh) |
MX (1) | MXPA05006917A (zh) |
NO (1) | NO20052993L (zh) |
PL (1) | PL377295A1 (zh) |
RU (1) | RU2005117789A (zh) |
TW (1) | TW200507839A (zh) |
UY (1) | UY28150A1 (zh) |
WO (1) | WO2004058255A1 (zh) |
ZA (1) | ZA200504953B (zh) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2543338A1 (en) * | 2003-10-24 | 2005-05-06 | Solvay Pharmaceuticals Gmbh | Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds |
US7410988B2 (en) | 2004-08-13 | 2008-08-12 | Genentech, Inc. | 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
RU2007119315A (ru) * | 2004-10-25 | 2008-11-27 | Зольвай Фармасьютиклз Гмбх (De) | Фармацевтические композиции, содержащие антагонисты каннабиноидного рецептора св1 и открыватели калиевых каналов, предназначенные для лечения сахарного диабета типа i, ожирения и связанных с ними состояний |
CN102633730A (zh) * | 2004-12-03 | 2012-08-15 | 先灵公司 | 作为cb1拮抗剂的取代哌嗪 |
TW200716576A (en) | 2005-06-07 | 2007-05-01 | Shionogi & Co | Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
NZ564759A (en) | 2005-06-30 | 2011-08-26 | Prosidion Ltd | GPCR agonists |
FR2894578B1 (fr) * | 2005-12-12 | 2008-02-01 | Sanofi Aventis Sa | Derives heterocycliques, leur preparation et leur application en therapeutique. |
WO2007114124A1 (ja) * | 2006-03-30 | 2007-10-11 | Shionogi & Co., Ltd. | I型11βヒドロキシステロイド脱水素酵素阻害活性を有するイソキサゾール誘導体およびイソチアゾール誘導体 |
BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
EP2377863A1 (en) | 2007-01-04 | 2011-10-19 | Prosidion Limited | Piperidine GPCR agonists |
US20100048625A1 (en) | 2007-01-04 | 2010-02-25 | Matthew Colin Thor Fyfe | Piperidine gpcr agonists |
GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
AR064735A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr y composicion farmaceutica en base al compuesto |
CL2008000017A1 (es) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
PT2215071E (pt) | 2007-11-30 | 2015-10-16 | Zynerba Pharmaceuticals Inc | Pró-fármacos de tetrahidrocanabinol, composição compreendendo pró-fármacos de tetrahidrocanabinol e metodos de utilização dos mesmos |
TW201014822A (en) | 2008-07-09 | 2010-04-16 | Sanofi Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
WO2010138901A1 (en) * | 2009-05-29 | 2010-12-02 | Biogen Idec Ma Inc | Carboxylic acid-containing compounds, derivatives thereof, and related methods of use |
DE102009038123A1 (de) | 2009-08-17 | 2011-02-24 | Aicuris Gmbh & Co. Kg | Substituierte (Thiazolyl-carbonyl)imidazolidinone und ihre Verwendung |
CN102482312A (zh) | 2009-08-26 | 2012-05-30 | 赛诺菲 | 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途 |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
WO2012120050A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
JP6522602B2 (ja) | 2013-07-02 | 2019-05-29 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Rock阻害剤としての三環式ピリド−カルボキサミド誘導体 |
CN105492444B (zh) | 2013-07-02 | 2018-09-07 | 百时美施贵宝公司 | 作为rock抑制剂的三环吡啶-甲酰胺衍生物 |
CN104327065A (zh) * | 2014-09-15 | 2015-02-04 | 湖南华腾制药有限公司 | 一种n-甲基-(喹啉-4-基)甲烷胺的制备方法 |
WO2021207469A1 (en) * | 2020-04-09 | 2021-10-14 | Baylor College Of Medicine | Novel inhibitors of histone acetyltransferase p300/cbp for cancer therapy |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4348385A (en) * | 1980-11-17 | 1982-09-07 | Mobay Chemical Corporation | Flowable pesticides |
US4610868A (en) * | 1984-03-20 | 1986-09-09 | The Liposome Company, Inc. | Lipid matrix carriers for use in drug delivery systems |
US4826689A (en) * | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
FR2608988B1 (fr) * | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules |
KR920003767B1 (ko) * | 1988-06-28 | 1992-05-14 | 마쓰시다 덴끼 산교오 가부시끼가이샤 | 배연(排煙) 정화장치 |
JP3003148B2 (ja) * | 1989-01-05 | 2000-01-24 | 藤沢薬品工業株式会社 | チアゾール化合物、その製造法およびそれを含有する医薬組成物 |
EP0461930B1 (en) * | 1990-06-15 | 1995-09-13 | Merck & Co. Inc. | A crystallization method to improve crystal structure and size |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
CA2125282C (en) * | 1991-12-05 | 1999-08-31 | Jens-Christian Wunderlich | Pharmaceutically applicable nanosol and process for preparing the same |
FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
US5468604A (en) * | 1992-11-18 | 1995-11-21 | Eastman Kodak Company | Photographic dispersion |
GB9319129D0 (en) * | 1993-09-15 | 1993-11-03 | Dowelanco Ltd | Storage and dilution of stable aqueous dispersions |
SE9303281D0 (sv) * | 1993-10-07 | 1993-10-07 | Astra Ab | New formulation |
SE9403846D0 (sv) * | 1994-11-09 | 1994-11-09 | Univ Ohio State Res Found | Small particle formation |
DE4440337A1 (de) * | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
US5665331A (en) * | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
DE69727244T2 (de) * | 1996-10-03 | 2004-11-25 | Hermes Biosciences Inc., San Francisco | Hydrophile Mikroteilchen und Verfahren zu deren Herstellung |
US6127520A (en) * | 1997-04-15 | 2000-10-03 | Regents Of The University Of Michigan | Compositions and methods for the inhibition of neurotransmitter uptake of synaptic vesicles |
FR2766368B1 (fr) * | 1997-07-24 | 2000-03-31 | Univ Claude Bernard Lyon | Procede de preparation de nanocapsules de type vesiculaire, utilisables notamment comme vecteurs colloidaux de principes actifs pharmaceutiques ou autres |
US6375986B1 (en) * | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
FR2789079B3 (fr) * | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
EP1205478A4 (en) * | 1999-08-06 | 2004-06-30 | Takeda Chemical Industries Ltd | P38MAP KINASE INHIBITORS |
US6372777B1 (en) * | 1999-12-23 | 2002-04-16 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
MXPA04001071A (es) * | 2001-08-06 | 2004-05-20 | Astrazeneca Ab | Dispersion acuosa que comprende nanoparticulas estables de un activo insoluble en agua y un excipiente como trigliceridos de cadena media (mct). |
JP2005532982A (ja) * | 2001-09-24 | 2005-11-04 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 肥満の処置のためのピロール誘導体の製造及び使用 |
US20060003012A9 (en) * | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
AR038966A1 (es) * | 2002-03-18 | 2005-02-02 | Solvay Pharm Bv | Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1 |
GB0216700D0 (en) * | 2002-07-18 | 2002-08-28 | Astrazeneca Ab | Process |
GB0302673D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
GB0302672D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
GB0302671D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
GB0314057D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
WO2004111033A1 (en) * | 2003-06-18 | 2004-12-23 | Astrazeneca Ab | 2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator. |
-
2002
- 2002-12-24 GB GBGB0230087.9A patent/GB0230087D0/en not_active Ceased
-
2003
- 2003-12-18 CA CA002511603A patent/CA2511603A1/en not_active Abandoned
- 2003-12-18 MX MXPA05006917A patent/MXPA05006917A/es not_active Application Discontinuation
- 2003-12-18 AU AU2003290280A patent/AU2003290280A1/en not_active Abandoned
- 2003-12-18 US US10/538,318 patent/US20060122229A1/en not_active Abandoned
- 2003-12-18 BR BR0317703-3A patent/BR0317703A/pt not_active Application Discontinuation
- 2003-12-18 TW TW092136000A patent/TW200507839A/zh unknown
- 2003-12-18 RU RU2005117789/04A patent/RU2005117789A/ru not_active Application Discontinuation
- 2003-12-18 PL PL377295A patent/PL377295A1/pl not_active Application Discontinuation
- 2003-12-18 WO PCT/GB2003/005542 patent/WO2004058255A1/en active Application Filing
- 2003-12-18 KR KR1020057011032A patent/KR20050085691A/ko not_active Application Discontinuation
- 2003-12-18 CN CNA2003801099550A patent/CN1753672A/zh active Pending
- 2003-12-18 JP JP2004563340A patent/JP2006516137A/ja not_active Withdrawn
- 2003-12-18 EP EP03782644A patent/EP1581214A1/en not_active Withdrawn
- 2003-12-22 AR ARP030104798A patent/AR042659A1/es unknown
- 2003-12-23 UY UY28150A patent/UY28150A1/es not_active Application Discontinuation
-
2005
- 2005-06-17 ZA ZA200504953A patent/ZA200504953B/en unknown
- 2005-06-17 NO NO20052993A patent/NO20052993L/no not_active Application Discontinuation
- 2005-07-11 CO CO05067917A patent/CO5580768A2/es not_active Application Discontinuation
- 2005-07-19 IS IS7945A patent/IS7945A/is unknown
Also Published As
Publication number | Publication date |
---|---|
EP1581214A1 (en) | 2005-10-05 |
UY28150A1 (es) | 2004-07-30 |
NO20052993D0 (no) | 2005-06-17 |
RU2005117789A (ru) | 2006-01-27 |
GB0230087D0 (en) | 2003-01-29 |
BR0317703A (pt) | 2005-11-22 |
NO20052993L (no) | 2005-07-25 |
KR20050085691A (ko) | 2005-08-29 |
MXPA05006917A (es) | 2005-08-18 |
US20060122229A1 (en) | 2006-06-08 |
IS7945A (is) | 2005-07-19 |
AR042659A1 (es) | 2005-06-29 |
JP2006516137A (ja) | 2006-06-22 |
WO2004058255A1 (en) | 2004-07-15 |
CA2511603A1 (en) | 2004-07-15 |
ZA200504953B (en) | 2006-04-26 |
CN1753672A (zh) | 2006-03-29 |
AU2003290280A1 (en) | 2004-07-22 |
PL377295A1 (pl) | 2006-01-23 |
CO5580768A2 (es) | 2005-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200507839A (en) | Therapeutic agents | |
MXPA04005990A (es) | Derivados de 5,6-diaril-pirazina-2-amida como antagonistas de cb1. | |
TW200503692A (en) | Therapeutic agents | |
AP1687A (en) | Therapeutic biaryl derivatives. | |
CY1108367T1 (el) | Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου | |
BR0108610A (pt) | Compostos azapolicìclicos condensados com arila | |
MXPA02012034A (es) | Derivados de tiofeno utiles como agentes anticancerosos. | |
HUP0000735A2 (hu) | Az Xa faktort gátló nitrogéntartalmú heteroaromás vegyületek | |
NZ333987A (en) | Inhibitors of cysteine and serine proteases particularly cathepsin K that are useful in the treatment of diseases that cause bone loss | |
UY25679A1 (es) | Derivados de quinolin-2-ona inhibidores de la farnesil proteína transferasa útiles como agentes contra el cáncer | |
WO2000040558A8 (en) | Aspartic protease inhibitors | |
EP0609441A4 (en) | Oxazolidone derivative. | |
HUP0203275A2 (hu) | 1-(Gyűrűs amino)-alkilciklohexán-származékok, ezeket tartalmazó görcsoldó hatású gyógyszerkészítmények, valamint ezek alkalmazása | |
DK74988A (da) | Hidtil ukendte peptidderivater, der har en polycyklisk nitrogenholdig struktur, fremgangsmaade til deres fremstilling og farmaceutiske midler indeholdende dem | |
EP1375496A4 (en) | N-ARYL SUBSTITUTED CYCLIC AMINE DERIVATIVE AND MEDICAMENT CONTAINING SAID DERIVATIVE AS ACTIVE INGREDIENT | |
DE69837334D1 (de) | Heterozyclische verbindungen, ihr herstellungsverfahren und diese enthaltende pharmazeutische zusammensetzungen | |
EP1142883A4 (en) | HETEROCYCLIC COMPOUNDS AND MEDICINAL COMPOSITIONS THAT CONTAIN THEM | |
NZ504298A (en) | 2,3-methano-amino acid compounds for treating serine protease disorders | |
DE68910090D1 (de) | Verwendung heterozyklischer Amide zur Verhinderung der Tumormetastasierung. | |
ATE245155T1 (de) | N-substituierte 1-(butyrolacton)-isochinoline zur behandlung von nervenstörungen | |
WO2005051953A3 (en) | Pyrrolo-pyrazine derivatives useful as cb1-modulators | |
HUT53487A (en) | Fungicide compositions containing nitrogen-containing heterocyclic compounds as active components and process for producing the active components | |
WO2001029017A3 (fr) | 3-AMINO-2,2-DI-C-ALKYL-1,4-BUTYROLACTONES ET 1,4-THIOBUTYROLACTONES N-SUBSTITUEES UTILES COMME STIMULANT DE L'ACTIVITE DE L'ACIDE η-AMINOBUTYRIQUE ET DANS LE TRAITEMENT DES TROUBLES NERVEUX ET LEUR PROCEDE DE PREPARATION | |
TH34367A (th) | สารต้านจุลชีพอะมิโนและไธโอแอลคิล เบนซอกแซซีนที่มีหมู่แทนที่ตำแหน่ง 2- | |
JO1648B1 (en) | Nitrogen compounds |